A cheap medicine that is often promoted by Podcaster and Fitness Fanatic Joe Rogan can lower the risk of colon cancer.
A new study showed that metformin – a pill of 20 cents used to manage type 2 diabetes – reduced the risk of developing the deadly disease by a maximum of 13 percent.
Israeli researchers followed 31,000 who names metformin for a maximum of five years.
In the end, patients who took the drug for three to five years had a 13 percent lower risk of developing colon cancer in the part of the colon that is most susceptible to tumors. Taking the medicine for one to three years was associated with a decrease in the risk by 10 percent.
Participants came from the database of veteran cases and most were more than 50 years old, but researchers said their results suggested that metformin could be used possible to prevent bowel cancer for wider groups.
Uncontrolled diabetes is a risk factor for the disease, so treating it generally can lower the risk of cancer, but the use of metformin can result in additional benefits, because earlier research has shown that the drug has been linked to delayed aging and reduced mortality.
The popular Podcaster Joe Rogan, 57, who has not revealed that if he uses the medicine himself, often talks about the medication on his podcast, with expert guests who praise the potential lifespan of the lifespan.
One guest, Harvard Anti -aging Scientist Dr. David Sinclair claimed that it could help to slow down – and in an interview with Dr. Sinclair In 2019, Rogan said: “I had to do a quack who is willing to prescribe metformin to me.”
A study suggests that metformin, which Joe Rogan has repeatedly mentioned on his popular podcast, could help to reduce the risk of colon cancer on the left side of the colon
Metformin is approved for type 2 diabetics, but is prescribed label for a series of ailments. Researchers also look at whether it can be used to combat aging
The study was unveiled on ASCO 2025, the world’s largest cancer conference that took place this week in Chicago, Illinois.
Although promising, scientists behind the newspaper did not explain why the medicine can be protective and said that their results had to be confirmed with more research.
Metformin is a medicine with only recipe approved for type 2 diabetics to help them arrange blood sugar levels, with patients taking about two pills a day – sometimes priced at just 20 cents per pill. It is estimated that more than 19 million Americans are prescribed every year.
But it is also prescribed off-label for a number of other disorders, including prediabetes and polycystic ovarian syndrome, a condition in which women experience cysts on their ovaries.
Scientists from the Jusidman Cancer Center in Israel analyzed data about patients in the Veterans Affairs database from 1999 to 2020.
They recruited patients on metformin and corresponded to patients with similar characteristics who are not on metformin.
These were usually less healthy patients, which increases the risk of a diagnosis or comorbidity of colon cancer.
In the metformin group, the majority of patients had used the material for at least five years.
In general, data was available at the location of the tumor for more than 113,000 patients in the study.
Of these, 13,691 were in the metformin group – including 9,588 (70 percent) that developed colon cancer on the left side of the colon.
About 100,000 people were in the non -metormin group – including 95,000 (95 percent) that developed the cancer on the left side of their colon.
Colon cancer is increasingly affecting young people. Bailey Hutchins van Tennessee (photo), died of colon cancer at the age of 26 –
The researchers work was published as an abstract Due to the American Society of Clinical Oncology and was not made available or Peer was assessed.
Previously published work, however, has found similar benefits.
A study from 2019 found that metformin was associated with a reduction of eight percent in colorectal cancer. On location it was associated with a reduction of 14 percent in the risk of cancer in the rectum.
A 2024 study looked at the expression of HCT116 cells – found in patient cancer patients. When these cells grow abnormally, this contributes to tumor progression, but metformin changed the expression of these cells.
Results showed that the medication recorded genes that can suppress the growth and distribution of colorectal cancer cells.
Another study from 2024 found that the use of the metformin was associated with ‘considerably lower’ colon cancer risk in both the colon and the rectum – about a decrease in the risk of approximately 30 percent.
And an increased protective effect was observed in white people and people with obesity.
Researchers concluded that the benefits of Metformin probably generalized to populations with a higher underlying risk. ‘
#Researchers #prove #theory #Joe #Rogan #20cent #meadow #bridge #millions #Americans #correct #colon #cancer #linked